

# Vicente Soriano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4609580/publications.pdf>

Version: 2024-02-01

805  
papers

32,105  
citations

5876

81  
h-index

10127

140  
g-index

859  
all docs

859  
docs citations

859  
times ranked

18851  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Treatment of hepatitis delta and <scp>HIV</scp> infection. <i>Liver International</i> , 2023, 43, 108-115.  | 1.9 | 4         |
| 2  | Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. <i>Aids</i> , 2022, 36, 249-256.  | 1.0 | 7         |
| 3  | Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 45-50.   | 1.5 | 11        |
| 4  | Another patient has cured HIV infection. <i>AIDS Reviews</i> , 2022, 23, 226-227.   | 0.5 | 0         |
| 5  | A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990&#8217;s. <i>AIDS Reviews</i> , 2022, 24, 50.  | 0.5 | 0         |
| 6  | Use of antibiotics in respiratory viral infections. <i>Internal and Emergency Medicine</i> , 2022, 17, 1569-1570.   | 1.0 | 2         |
| 7  | Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. <i>HIV Medicine</i> , 2022, 23, 639-649.  | 1.0 | 3         |
| 8  | Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. <i>Journal of Viral Hepatitis</i> , 2022, 29, 777-784.  | 1.0 | 6         |
| 9  | The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America. <i>Journal of Clinical Virology</i> , 2022, 153, 105195. | 1.6 | 0         |
| 10 | Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. <i>Hepatology International</i> , 2022, 16, 1161-1169.   | 1.9 | 4         |
| 11 | Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.  | 1.0 | 6         |
| 12 | Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. <i>AIDS Reviews</i> , 2021, 22, 44-56.   | 0.5 | 10        |
| 13 | Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. <i>Clinical Infectious Diseases</i> , 2021, 72, 1101-1102.   | 2.9 | 15        |
| 14 | COVID-19 Comes 40 Years After AIDS - Any Lesson?. <i>AIDS Reviews</i> , 2021, 22, 63-77.  | 0.5 | 4         |
| 15 | Clinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation. <i>Transplantation Proceedings</i> , 2021, 53, 743-745.   | 0.3 | 1         |
| 16 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e754-e764.                                     | 2.9 | 160       |
| 17 | Situaci3n epidemiol3gica actual de la infecci3n por VIH-2 y HTLV-1 en Espa±a. <i>Medicina Cl3nica</i> , 2021, 156, 290-296.   | 0.3 | 1         |
| 18 | The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , 2021, 23, 40-47.  | 0.5 | 66        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Current epidemiological status of HIV-2 and HTLV-1 infection in Spain. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT 6 Overloc   | 0.1 | 0         |
| 20 | New SARS-CoV-2 Variants Challenge Vaccines Protection. <i>AIDS Reviews</i> , 2021, 23, 57-58.   | 0.5 | 8         |
| 21 | Main differences between the first and second waves of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 105, 374-376.   | 1.5 | 92        |
| 22 | The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.  | 1.9 | 20        |
| 23 | Considerations on HTLV-1 infection in Spain. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 578.  | 0.1 | 0         |
| 24 | COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter. <i>AIDS Reviews</i> , 2021, 23, 115-116.  | 0.5 | 0         |
| 25 | Third wave of COVID-19 in Madrid, Spain. <i>International Journal of Infectious Diseases</i> , 2021, 107, 212-214.  | 1.5 | 38        |
| 26 | Consideraciones sobre la infección por HTLV-1 en España. <i>Medicina Clínica</i> , 2021, 156, 578.  | 0.3 | 0         |
| 27 | Hepatitis delta in patients hospitalized in Spain (1997-2018). <i>Aids</i> , 2021, 35, 2311-2318.   | 1.0 | 7         |
| 28 | Short Communication: Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 610-612.   | 0.5 | 6         |
| 29 | Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. <i>International Journal of Infectious Diseases</i> , 2021, 112, 81-88.  | 1.5 | 21        |
| 30 | Envisioning a hepatitis delta cure with new antivirals. <i>Future Microbiology</i> , 2021, 16, 927-930.   | 1.0 | 8         |
| 31 | Unveiling Long COVID-19 Disease. <i>AIDS Reviews</i> , 2021, 22, 227-228.   | 0.5 | 6         |
| 32 | A Key Action Plan for EDUCATION in a Global Crisis. <i>Lecture Notes in Educational Technology</i> , 2021, , 263-272.   | 0.5 | 0         |
| 33 | Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639. | 1.3 | 7         |
| 34 | Tough requirements for new antiretroviral drugs. <i>Lancet HIV</i> , 2020, 7, e150-e151.  | 2.1 | 2         |
| 35 | The Resurgence of Medical Ethics During the Coronavirus Disease (COVID)-19 Outbreak. <i>AIDS Reviews</i> , 2020, 22, 123-124.   | 0.5 | 3         |
| 36 | Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections. <i>AIDS Reviews</i> , 2020, 22, 124-127.  | 0.5 | 2         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Long-acting antiretroviral therapy. <i>Nature Materials</i> , 2020, 19, 826-827.   | 13.3 | 16        |
| 38 | Advances in hepatitis B therapeutics. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096502.  | 1.1  | 26        |
| 39 | Keeping alive enterprises while embracing unprecedented COVID-19 restrictions. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612092017.   | 1.1  | 4         |
| 40 | Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , 2020, 34, 1019-1027.  | 1.0  | 20        |
| 41 | Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. <i>International Journal of Infectious Diseases</i> , 2020, 97, 290-292.   | 1.5  | 97        |
| 42 | Why such excess of mortality for COVID-19 in Spain?. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612093275.   | 1.1  | 16        |
| 43 | Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. <i>Journal of Infectious Diseases</i> , 2020, 221, 1962-1972.   | 1.9  | 14        |
| 44 | Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains. <i>Emerging Microbes and Infections</i> , 2020, 9, 913-923.                                      | 3.0  | 9         |
| 45 | HTLV-1 infection and health outcomes. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 407-408.  | 4.6  | 8         |
| 46 | Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020, 17, 41-48.   | 2.1  | 9         |
| 47 | Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. <i>AIDS Reviews</i> , 2020, 22, 168-172.   | 0.5  | 3         |
| 48 | Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612098212.  | 1.1  | 3         |
| 49 | Acute Viral Hepatitis in Men Having Sex with Men. <i>AIDS Reviews</i> , 2020, 22, 168-172.   | 0.5  | 0         |
| 50 | HTLV-1 infection in solid organ transplant donors and recipients in Spain. <i>BMC Infectious Diseases</i> , 2019, 19, 706.   | 1.3  | 20        |
| 51 | HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019, 33, e13670.   | 0.8  | 8         |
| 52 | Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611986802. | 1.1  | 7         |
| 53 | Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611985146.       | 1.1  | 7         |
| 54 | JÃ©rÃªme Lejeune passed away 25 years ago. <i>Hereditas</i> , 2019, 156, 18.   | 0.5  | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.  | 1.8 | 341       |
| 56 | HIV co-infection in HTLV-1 carriers in Spain. <i>Virus Research</i> , 2019, 266, 48-51.   | 1.1 | 14        |
| 57 | Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz036.   | 0.4 | 8         |
| 58 | Hepatitis Delta Estimates in the United States Revisited. <i>Clinical Infectious Diseases</i> , 2019, 69, 1833-1834.  | 2.9 | 1         |
| 59 | Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz070.                           | 0.4 | 20        |
| 60 | Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1357-1362.   | 1.3 | 16        |
| 61 | Occult hepatitis B and HIV infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1403-1407.   | 0.8 | 12        |
| 62 | Treatment outcome in dually HIV-1 and HIV-2 coinfecting patients living in Spain. <i>Aids</i> , 2019, 33, 2167-2172.  | 1.0 | 7         |
| 63 | Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS. <i>AIDS Reviews</i> , 2019, 20, 187-204.  | 0.5 | 15        |
| 64 | HTLV-1 Infection is Rising Up in Spain Whereas HTLV-2 is Vanishing. <i>AIDS Reviews</i> , 2019, 21, 233-235.  | 0.5 | 4         |
| 65 | Decline and Changing Profile of Hepatitis Delta among Injection Drug users in Spain. <i>Antiviral Therapy</i> , 2018, 23, 87-90.  | 0.6 | 16        |
| 66 | Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges. <i>Cancer</i> , 2018, 124, 1647-1649.   | 2.0 | 13        |
| 67 | Hepatitis Delta Enters a New Therapeutic Era. <i>Journal of Infectious Diseases</i> , 2018, 217, 1173-1176.   | 1.9 | 8         |
| 68 | Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.  | 1.3 | 38        |
| 69 | Short article: Hepatitis delta in patients with resolved hepatitis B virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1063-1065.   | 0.8 | 8         |
| 70 | Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx228. | 0.4 | 11        |
| 71 | AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities. <i>Viruses</i> , 2018, 10, 293.  | 1.5 | 9         |
| 72 | Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1060-1062.  | 0.8 | 20        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Report from the International Conference on Viral Hepatitis (ICVH) â€“ Chicago, October 2017. AIDS Reviews, 2018, 20, .   | 0.5 | 18        |
| 74 | Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health. Journal of Virus Eradication, 2018, 4, 196-207. | 0.3 | 1         |
| 75 | Report from the International Conference on Viral Hepatitis - 2017. AIDS Reviews, 2018, 20, 58-70.  | 0.5 | 5         |
| 76 | Hepatitis B Gene Therapy Coming to Age. AIDS Reviews, 2018, 20, 125-127.  | 0.5 | 5         |
| 77 | Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. Antiviral Therapy, 2017, 22, 307-312.  | 0.6 | 50        |
| 78 | Human T-Lymphotropic Virus Infection in Hepatitis C Virusâ€“Antibody Positive Patients in Spain. AIDS Research and Human Retroviruses, 2017, 33, 1013-1017.   | 0.5 | 0         |
| 79 | HIV type 2 epidemic in Spain. Aids, 2017, 31, 1353-1364.  | 1.0 | 18        |
| 80 | Human T-lymphotropic virus type 1 infection and disease in Spain. Aids, 2017, 31, 1653-1663.  | 1.0 | 30        |
| 81 | Hepatitis delta and HIV infection. Aids, 2017, 31, 875-884.   | 1.0 | 35        |
| 82 | Dual antiretroviral therapy for HIV infection. Expert Opinion on Drug Safety, 2017, 16, 923-932.  | 1.0 | 47        |
| 83 | Characterization of Free Phenytoin Concentrations in End-Stage Renal Disease Using the Winter-Tozer Equation. Annals of Pharmacotherapy, 2017, 51, 669-674.   | 0.9 | 15        |
| 84 | New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 2017, 26, 843-851.  | 1.9 | 43        |
| 85 | Treatment of hepatitis C with new fixed dose combinations. Expert Opinion on Pharmacotherapy, 2017, 18, 1235-1242.  | 0.9 | 23        |
| 86 | Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. Journal of Antimicrobial Chemotherapy, 2017, 72, 2083-2088.   | 1.3 | 27        |
| 87 | Antiretroviral treatment of HIV-2 infection. Future Virology, 2017, 12, 461-472.  | 0.9 | 4         |
| 88 | Need to Face Liver Cirrhosis after HCV Cure with Antivirals. EBioMedicine, 2017, 24, 24-25.   | 2.7 | 6         |
| 89 | Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1015-1022.   | 1.5 | 13        |
| 90 | Is Ribavirin Teratogenic in Humans? No Evidence So Far. Drug Safety, 2017, 40, 1163-1165.   | 1.4 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 807-816.   | 1.5 | 16        |
| 92  | Impact of <i>ITPA</i> Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C. Antiviral Therapy, 2017, 22, 571-575.                                     | 0.6 | 6         |
| 93  | CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.                 | 1.3 | 17        |
| 94  | Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. PLoS ONE, 2017, 12, e0184329.  | 1.1 | 6         |
| 95  | Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis. AIDS Reviews, 2017, 19, 54-55.  | 0.5 | 3         |
| 96  | A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy. AIDS Reviews, 2017, 19, 113-114.  | 0.5 | 1         |
| 97  | Hepatitis A Outbreaks in European Homosexual Men. AIDS Reviews, 2017, 19, 113-114.   | 0.5 | 8         |
| 98  | Hepatic Decompensation with Sofosbuvir plus Simeprevir in a Patient with Child-Pugh B Compensated Cirrhosis. Antiviral Therapy, 2016, 21, 91-92.   | 0.6 | 18        |
| 99  | Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID). Journal of Virus Eradication, 2016, 2, 187-192.   | 0.3 | 0         |
| 100 | HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012). Revista Do Instituto De Medicina Tropical De Sao Paulo, 2016, 58, 11.      | 0.5 | 11        |
| 101 | <i>IL15</i> polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Liver International, 2016, 36, 1258-1266. | 1.9 | 5         |
| 102 | Tenofovir for Hepatitis Delta. Hepatology, 2016, 63, 1395-1396.  | 3.6 | 8         |
| 103 | Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1197-1209.   | 1.5 | 41        |
| 104 | Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. European Journal of Gastroenterology and Hepatology, 2016, 28, 923-926.    | 0.8 | 1         |
| 105 | Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology, 2016, 63, 2065-2066.  | 3.6 | 16        |
| 106 | Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. Journal of Translational Medicine, 2016, 14, 257.                                   | 1.8 | 20        |
| 107 | Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. Journal of Infection, 2016, 72, 587-596.                                   | 1.7 | 60        |
| 108 | Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opinion on Pharmacotherapy, 2016, 17, 1215-1223.  | 0.9 | 53        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in <sc>HIV</sc>-positive patients. Journal of Viral Hepatitis, 2016, 23, 47-52.   | 1.0 | 57        |
| 110 | High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. Antiviral Therapy, 2016, 21, 489-494.  | 0.6 | 6         |
| 111 | Is HIV still a special population for the treatment of hepatitis C?. Aids, 2016, 30, 2001-2003.  | 1.0 | 4         |
| 112 | Infection-related and -unrelated malignancies, <sc>HIV</sc> and the aging population. HIV Medicine, 2016, 17, 590-600.   | 1.0 | 37        |
| 113 | The global spread of HIV-1 subtype B epidemic. Infection, Genetics and Evolution, 2016, 46, 169-179.   | 1.0 | 60        |
| 114 | Acute hepatitis C virus re-infection in a heterosexual <sc>HIV</sc>-positive partner. Liver International, 2016, 36, 763-763.  | 1.9 | 5         |
| 115 | Host and disease factors are associated with cognitive function in European <sc>HIV</sc>-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.   | 1.0 | 7         |
| 116 | SOLAR-2: the sun also rises for cirrhotics. Lancet Infectious Diseases, The, 2016, 16, 624-625.  | 4.6 | 1         |
| 117 | Delta hepatitis: new approaches to therapy. Future Virology, 2016, 11, 197-205.  | 0.9 | 0         |
| 118 | Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062. | 1.3 | 22        |
| 119 | New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy, 2016, 17, 217-229.   | 0.9 | 22        |
| 120 | Short Communication: <i>CXCL12</i> rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Research and Human Retroviruses, 2016, 32, 226-231.      | 0.5 | 0         |
| 121 | MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. PLoS ONE, 2016, 11, e0155245.   | 1.1 | 22        |
| 122 | Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): 25-27 May, Marseille, France. Journal of Virus Eradication, 2016, 2, 187-92.  | 0.3 | 0         |
| 123 | Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. AIDS Reviews, 2016, 18, 81-8.   | 0.5 | 1         |
| 124 | Reactivation of Hepatitis B in HIV Patients Treated for Hepatitis C. AIDS Reviews, 2016, 18, 222-223.  | 0.5 | 4         |
| 125 | Liver Fibrosis Progression despite HCV Cure with Antiviral Therapy in HIV-HCV-Coinfected Patients. Antiviral Therapy, 2015, 20, 329-334.   | 0.6 | 16        |
| 126 | Corrigendum. HIV Clinical Trials, 2015, 16, 236-238.   | 2.0 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 309-315.   | 1.5 | 24        |
| 128 | IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015, 29, 1895-1897.   | 1.0 | 19        |
| 129 | Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0139981.                   | 1.1 | 45        |
| 130 | Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> , 2015, 16, 72-80.                      | 2.0 | 8         |
| 131 | Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 179-186.  | 0.9 | 7         |
| 132 | TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. <i>Journal of Clinical Virology</i> , 2015, 65, 62-67.   | 1.6 | 6         |
| 133 | Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291. | 1.4 | 10        |
| 134 | Dolutegravir for the treatment of HIV-2 infection. <i>Journal of Clinical Virology</i> , 2015, 64, 12-15.  | 1.6 | 30        |
| 135 | Drug interactions with new hepatitis C oral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 333-341.  | 1.5 | 46        |
| 136 | Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs. <i>Virology Journal</i> , 2015, 12, 4.  | 1.4 | 4         |
| 137 | Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.  | 3.9 | 119       |
| 138 | Emerging Challenges in Managing Hepatitis B in HIV Patients. <i>Current HIV/AIDS Reports</i> , 2015, 12, 344-352.  | 1.1 | 23        |
| 139 | Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1027-1032.   | 2.8 | 12        |
| 140 | Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.                    | 3.9 | 188       |
| 141 | Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.  | 1.9 | 33        |
| 142 | Faldaprevir and pegylated interferon $\alpha$ -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.   | 1.0 | 17        |
| 143 | Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1421-1434.   | 1.0 | 17        |
| 144 | Changing utilization of Stavudine (d4T) in HIV-positive people in 2006–2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015, 16, 533-543.  | 1.0 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. Journal of Clinical Virology, 2015, 71, 63-66.   | 1.6 | 12        |
| 146 | Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <sc>SOUND</sc>â€ƒ3, a Phase 2b study. Liver International, 2015, 35, 417-421.   | 1.9 | 18        |
| 147 | Gene therapy for HIV infection. Expert Opinion on Biological Therapy, 2015, 15, 319-327.   | 1.4 | 8         |
| 148 | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004.  | 1.1 | 5         |
| 149 | Caution with new oral hepatitis C drugs. AIDS Reviews, 2015, 17, 121-2.  | 0.5 | 5         |
| 150 | The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. AIDS Reviews, 2015, 17, 212-9.   | 0.5 | 9         |
| 151 | Non-Human Cancers in AIDS Patients. AIDS Reviews, 2015, 17, 238-9.   | 0.5 | 0         |
| 152 | IFNL4 ss469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. PLoS ONE, 2014, 9, e95515.                                      | 1.1 | 24        |
| 153 | Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004â€ƒ2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. PLoS ONE, 2014, 9, e116226.                        | 1.1 | 19        |
| 154 | Very Late HCV Relapse following Triple Therapy for Hepatitis C. Antiviral Therapy, 2014, 19, 723-724.  | 0.6 | 5         |
| 155 | Management and treatment of chronic hepatitis B in HIV-positive patients. Annals of Medicine, 2014, 46, 290-296.   | 1.5 | 11        |
| 156 | Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2014, 18, 700-708.  | 0.6 | 11        |
| 157 | A polymorphism linked to <i><sc>RRAS</sc></i>, <i><sc>SCAF</sc>1</i>, <i><sc>IRF</sc>3</i> and <i><sc>BCL</sc>2L12</i> genes is associated with cirrhosis in hepatitis C virus carriers. Liver International, 2014, 34, 558-566. | 1.9 | 9         |
| 158 | Changes in liver fibrosis in <sc>HIV</sc>/<sc>HCV</sc>â€ƒcoinfected patients following different outcomes with peginterferon plus ribavirin therapy. Journal of Viral Hepatitis, 2014, 21, 475-479.                              | 1.0 | 16        |
| 159 | Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. Aids, 2014, 28, 2389-2394.  | 1.0 | 56        |
| 160 | HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. Journal of Antimicrobial Chemotherapy, 2014, 69, 2191-2194.   | 1.3 | 5         |
| 161 | PPARÎ³2 Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 113-119.                     | 0.9 | 5         |
| 162 | X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. Aids, 2014, 28, 1603-1609.  | 1.0 | 14        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014, 28, 1473-1478.  | 1.0 | 24        |
| 164 | Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 739-748.                                   | 0.8 | 31        |
| 165 | P750 SPONTANEOUS HCV CLEARANCE IN HIV PATIENTS WITH CHRONIC HEPATITIS C BEARING FAVORABLE IL28B ALLELES ON ANTIRETROVIRAL THERAPY. <i>Journal of Hepatology</i> , 2014, 60, S321.   | 1.8 | 0         |
| 166 | Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1549-1553.  | 2.9 | 85        |
| 167 | High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. <i>HIV Medicine</i> , 2014, 15, n/a-n/a.  | 1.0 | 4         |
| 168 | European mitochondrial haplogroups are not associated with hepatitis C virus (<sc>HCV</sc>) treatment response in <sc>HIV</sc>/<sc>HCV</sc>-coinfected patients. <i>HIV Medicine</i> , 2014, 15, 425-430.   | 1.0 | 5         |
| 169 | Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377. | 1.7 | 3         |
| 170 | A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762.   | 2.3 | 4         |
| 171 | Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1051-1057.   | 0.9 | 10        |
| 172 | Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014, 105, 1-7.   | 1.9 | 24        |
| 173 | Emerging antiretroviral drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 211-219.  | 0.9 | 19        |
| 174 | Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1119-1130.  | 1.5 | 11        |
| 175 | Molecular Epidemiology and Clinical Features of Human T Cell Lymphotropic Virus Type 1 Infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 856-862.   | 0.5 | 10        |
| 176 | Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014, 19, 799-803.  | 0.6 | 9         |
| 177 | Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2014, 20, 65-72.  | 0.6 | 16        |
| 178 | ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 27-32.   | 0.9 | 8         |
| 179 | Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.   | 1.1 | 35        |
| 180 | HIV-2 and HTLV-1 infections in Spain, a non-endemic region. <i>AIDS Reviews</i> , 2014, 16, 152-9.  | 0.5 | 8         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 181 | RNA viruses at the forefront of human infections - HIV, hepatitis C, and now Ebola. <i>AIDS Reviews</i> , 2014, 16, 246-7.  | 0.5  | 3         |
| 182 | Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1161-1170.  | 0.9  | 57        |
| 183 | Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013, 85, 1734-1740.  | 2.5  | 8         |
| 184 | Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234.   | 1.1  | 48        |
| 185 | Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 630-639.   | 13.9 | 215       |
| 186 | Strategic use of lamivudine in the management of chronic hepatitis B. <i>Antiviral Research</i> , 2013, 100, 435-438.   | 1.9  | 15        |
| 187 | Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013, 12, 269-275.  | 0.3  | 3         |
| 188 | Pegylated interferon plus ribavirin is suboptimal in $\Delta$ IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.  | 1.7  | 10        |
| 189 | Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1117-1122.  | 2.9  | 27        |
| 190 | Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. <i>Journal of Neurology</i> , 2013, 260, 2551-2555.  | 1.8  | 21        |
| 191 | HIV gag-specific immune response mediated by double negative (CD3 <sup>+</sup> CD4 <sup>+</sup> CD8 <sup>-</sup> ) T cells in HIV-exposed seronegative individuals. <i>Journal of Medical Virology</i> , 2013, 85, 200-209. | 2.5  | 11        |
| 192 | Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501.  | 1.0  | 24        |
| 193 | Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. <i>Journal of Hepatology</i> , 2013, 59, 213-220.  | 1.8  | 41        |
| 194 | Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013, 58, 391-395.                     | 1.6  | 10        |
| 195 | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. <i>European Journal of Immunology</i> , 2013, 43, 499-509.          | 1.6  | 16        |
| 196 | Antiretroviral drug-related toxicities – clinical spectrum, prevention, and management. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 697-707.   | 1.0  | 23        |
| 197 | <i>IL28RA</i> polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus (HIV)-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 358-366.             | 1.0  | 17        |
| 198 | The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40.   | 1.9  | 24        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1231-1238.  | 1.0 | 15        |
| 200 | Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. <i>Aids</i> , 2013, 27, 2219-2224.   | 1.0 | 15        |
| 201 | Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013, 27, 81-85.  | 1.0 | 55        |
| 202 | Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver. <i>Clinical Infectious Diseases</i> , 2013, 56, 560-566.  | 2.9 | 20        |
| 203 | Hepatitis B, C, and D and HIV Infections among Immigrants from Equatorial Guinea Living in Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 789-794.  | 0.6 | 27        |
| 204 | HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385.   | 1.0 | 15        |
| 205 | Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189.   | 1.0 | 53        |
| 206 | Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468.   | 2.9 | 96        |
| 207 | Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.                                      | 1.3 | 9         |
| 208 | Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1517-1527.   | 1.8 | 18        |
| 209 | Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2616-2625.    | 1.3 | 14        |
| 210 | A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921. | 1.3 | 4         |
| 211 | Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. <i>HIV Medicine</i> , 2013, 14, 614-623.   | 1.0 | 46        |
| 212 | Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. <i>Liver International</i> , 2013, 33, 1357-1362.   | 1.9 | 45        |
| 213 | Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. <i>HIV Medicine</i> , 2013, 14, 370-378.                                  | 1.0 | 16        |
| 214 | Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 5-16.   | 1.5 | 15        |
| 215 | Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy. <i>Antiviral Therapy</i> , 2013, 19, 287-292.                                | 0.6 | 6         |
| 216 | Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-HCV-coinfected patients. <i>Aids</i> , 2013, 27, 1187-1188.   | 1.0 | 22        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.                           | 1.0 | 7         |
| 218 | Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013, 27, 1129-1134.                             | 1.0 | 24        |
| 219 | Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. <i>Aids</i> , 2013, 27, 687-696. | 1.0 | 10        |
| 220 | Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 163-173.  | 1.0 | 12        |
| 221 | Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.                              | 0.6 | 12        |
| 222 | Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035.   | 0.6 | 10        |
| 223 | Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.                                  | 1.1 | 25        |
| 224 | Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.                                   | 2.0 | 179       |
| 225 | The changing epidemiology of liver disease in HIV patients. <i>AIDS Reviews</i> , 2013, 15, 25-31.  | 0.5 | 38        |
| 226 | Cardiovascular Disease Risk in HIV Infection and Endothelial Progenitor Cells. <i>Journal of Infectious Diseases</i> , 2012, 206, 1479-1480.  | 1.9 | 3         |
| 227 | Antiviral effect of raltegravir on HTLV-1 carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 218-221.   | 1.3 | 39        |
| 228 | Inpatient and Outpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235.  | 1.0 | 30        |
| 229 | Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms. <i>Clinical Infectious Diseases</i> , 2012, 55, e1-e4. | 2.9 | 25        |
| 230 | Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.            | 1.4 | 62        |
| 231 | Management and Treatment of Chronic Hepatitis C in HIV Patients. <i>Seminars in Liver Disease</i> , 2012, 32, 138-146.  | 1.8 | 25        |
| 232 | HIV and Liver Disease. <i>Seminars in Liver Disease</i> , 2012, 32, 101-102.  | 1.8 | 0         |
| 233 | Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1007-1014.  | 0.9 | 14        |
| 234 | Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1262-1264.           | 0.5 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Prevalence of Xenotropic Murine Leukemia Virus-Related Virus Infection in Different Risk Populations in Spain. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1089-1094.  | 0.5 | 6         |
| 236 | Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 656-659.                                       | 0.5 | 17        |
| 237 | Drug resistance testing in hepatitis C therapy. <i>Future Virology</i> , 2012, 7, 309-321.   | 0.9 | 9         |
| 238 | Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164.  | 0.5 | 18        |
| 239 | Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay. <i>Journal of Clinical Microbiology</i> , 2012, 50, 569-572.   | 1.8 | 41        |
| 240 | Short Communication: RNASEL Alleles and Susceptibility to Infection by Human Retroviruses and Hepatitis Viruses. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1259-1261.  | 0.5 | 2         |
| 241 | Pharmacogenetics of hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 523-529.   | 1.3 | 30        |
| 242 | Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. <i>Aids</i> , 2012, 26, 1387-1392.   | 1.0 | 64        |
| 243 | Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor. <i>Antiviral Therapy</i> , 2012, 17, 921-926.   | 0.6 | 44        |
| 244 | B3 Identification of Neutralizing Antibodies and Their Epitopes From HIV Controllers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 74.  | 0.9 | 0         |
| 245 | Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. <i>Aids</i> , 2012, 26, 551-557.   | 1.0 | 9         |
| 246 | Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926.   | 1.0 | 62        |
| 247 | Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. <i>Journal of Infectious Diseases</i> , 2012, 205, 376-383.  | 1.9 | 31        |
| 248 | Author's response: expert reviews: who are they for?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1217-1218.  | 0.9 | 0         |
| 249 | Treatment failure with new hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 313-323.  | 0.9 | 30        |
| 250 | Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2020-2028. | 1.3 | 35        |
| 251 | A New Era for Hepatitis C – New Diagnostics Tools and New Weapons. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 440-441.  | 1.3 | 5         |
| 252 | Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794.   | 1.8 | 34        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Different impact of IL28B polymorphisms on response to peginterferon- $\alpha$ plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.   | 1.6 | 12        |
| 254 | Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68. | 0.9 | 7         |
| 255 | Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. <i>AIDS Research and Therapy</i> , 2012, 9, 23.  | 0.7 | 2         |
| 256 | Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.  | 1.0 | 14        |
| 257 | Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948.  | 1.9 | 7         |
| 258 | Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.  | 1.1 | 32        |
| 259 | Long-Term Use of Atazanavir in the Treatment of HIV-Infected patients. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S5764.  | 0.4 | 2         |
| 260 | Impact of IL28B gene polymorphisms on interferon- $\alpha$ 3 plasma levels during pegylated interferon- $\alpha$ /ribavirin therapy for chronic hepatitis C in patients coinfecting with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1246-1249.                      | 1.3 | 27        |
| 261 | No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfecting patients. <i>Antiviral Research</i> , 2012, 95, 67-71.   | 1.9 | 2         |
| 262 | Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. <i>AIDS Reviews</i> , 2012, 14, 223-30.   | 0.5 | 34        |
| 263 | Emerging viral infections--a potential threat for blood supply in the 21st century. <i>AIDS Reviews</i> , 2012, 14, 279-89.  | 0.5 | 24        |
| 264 | Elite Controllers Display Higher Activation on Central Memory CD8 T Cells Than HIV Patients Successfully on HAART. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 157-165.  | 0.5 | 26        |
| 265 | Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 457-477.   | 1.5 | 36        |
| 266 | Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. <i>Journal of Clinical Virology</i> , 2011, 51, 192-194.  | 1.6 | 6         |
| 267 | HTLV infection among foreign pregnant women living in Spain. <i>Journal of Clinical Virology</i> , 2011, 52, 119-122.  | 1.6 | 24        |
| 268 | European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , 2011, 11, 394-407.  | 4.6 | 218       |
| 269 | The expansion ability but not the quality of HIV-specific CD8+ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. <i>Immunology</i> , 2011, 134, 305-313.   | 2.0 | 4         |
| 270 | HBV primary drug resistance in newly diagnosed HIV+HBV-coinfecting individuals in Spain. <i>Antiviral Therapy</i> , 2011, 16, 585-589.   | 0.6 | 18        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | Resistance data in the ARTEN trial. <i>Antiviral Therapy</i> , 2011, 16, 1135-1136.   | 0.6 | 1         |
| 272 | A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 51-58. | 0.9 | 12        |
| 273 | Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. <i>Aids</i> , 2011, 25, 269-271.   | 1.0 | 26        |
| 274 | Hepatitis delta in HIV-infected individuals in Europe. <i>Aids</i> , 2011, 25, 1987-1992.   | 1.0 | 79        |
| 275 | Noncirrhotic portal hypertension in HIV infection. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 12-18.   | 1.3 | 34        |
| 276 | Host genetics. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 491-500.   | 1.5 | 5         |
| 277 | Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV+hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011, 25, 1131-1133.   | 1.0 | 20        |
| 278 | New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. <i>Aids</i> , 2011, 25, 1013-1014.   | 1.0 | 11        |
| 279 | Natural Polymorphisms Associated with Resistance to New Antivirals against HCV in Newly Diagnosed HIV+HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2011, 16, 413-416.  | 0.6 | 37        |
| 280 | Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675.   | 0.6 | 16        |
| 281 | Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. <i>Antiviral Therapy</i> , 2011, 16, 339-348.  | 0.6 | 89        |
| 282 | Predicted effect of direct acting antivirals in the current HIV+HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2011, 17, 571-575.   | 0.6 | 13        |
| 283 | Elevated TGF- $\beta$ 1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011, 41, 70-76.  | 1.7 | 21        |
| 284 | Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, 11-16.   | 1.0 | 67        |
| 285 | Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, 325-330.  | 1.0 | 31        |
| 286 | Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. <i>Journal of Viral Hepatitis</i> , 2011, 18, 542-548.  | 1.0 | 3         |
| 287 | Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011, 12, 487-493.   | 1.0 | 16        |
| 288 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). <i>HIV Medicine</i> , 2011, 12, 374-382.            | 1.0 | 30        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. <i>Journal of Infection</i> , 2011, 63, 382-390.  | 1.7 | 19        |
| 290 | Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience. <i>Antiviral Research</i> , 2011, 90, 164-167.   | 1.9 | 48        |
| 291 | Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. <i>Clinical Immunology</i> , 2011, 139, 110-114.  | 1.4 | 60        |
| 292 | HCV and HIV Coinfection. <i>Current Hepatitis Reports</i> , 2011, 10, 52-61.  | 0.3 | 1         |
| 293 | Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 633-638.   | 0.5 | 14        |
| 294 | Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1043-1045.   | 0.5 | 11        |
| 295 | Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3 <sup>rd</sup> Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3729-3742. | 1.4 | 23        |
| 296 | Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 641-644.   | 1.3 | 15        |
| 297 | Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus–Hepatitis C Virus–Coinfected Patients Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 203, 1629-1636.  | 1.9 | 55        |
| 298 | Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2838-2842.   | 1.3 | 19        |
| 299 | An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHI E V 2E Quality Control Study. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3491-3497.  | 1.8 | 29        |
| 300 | Drug resistance mutations in patients infected with HIV-2 living in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1484-1488.  | 1.3 | 29        |
| 301 | Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. <i>Journal of Infectious Diseases</i> , 2011, 204, 145-153.  | 1.9 | 102       |
| 302 | Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2011, 53, 1291-1295.   | 2.9 | 16        |
| 303 | Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group. <i>Clinical Infectious Diseases</i> , 2011, 52, 1257-1266.   | 2.9 | 41        |
| 304 | Directly acting antivirals against hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1673-1686.   | 1.3 | 81        |
| 305 | Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients. <i>Aids</i> , 2011, 25, 2197-2208.   | 1.0 | 33        |
| 306 | Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. <i>Aids</i> , 2011, 25, 73-79.  | 1.0 | 74        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 307 | Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011, 25, 761-766.  | 1.0 | 26        |
| 308 | High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3380-3382. | 1.8 | 18        |
| 309 | Short Communication: Severe Immune Suppression in Patients Infected with R5-Tropic HIV-1 Strains Is Associated with Increased gp120 Net Charge at Variable Regions. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 965-967.                | 0.5 | 9         |
| 310 | Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 139-144.                                       | 1.9 | 32        |
| 311 | A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.   | 1.9 | 19        |
| 312 | Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. <i>Aids</i> , 2011, 25, 399-409.   | 1.0 | 126       |
| 313 | Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. <i>Aids</i> , 2010, 24, 1171-1176.  | 1.0 | 84        |
| 314 | Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.   | 1.0 | 13        |
| 315 | Frequent hepatitis B virus rebound among HIV and hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.  | 1.0 | 59        |
| 316 | High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , 2010, 24, 467-469.   | 1.0 | 34        |
| 317 | Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066.   | 1.0 | 120       |
| 318 | Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 881-886.   | 0.6 | 35        |
| 319 | Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010, 85, 303-315.  | 1.9 | 177       |
| 320 | Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. <i>Antiviral Research</i> , 2010, 88, 152-159.   | 1.9 | 11        |
| 321 | Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption. <i>Retrovirology</i> , 2010, 7, .  | 0.9 | 0         |
| 322 | Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and cockcroft & gault (cg) and modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients. <i>Retrovirology</i> , 2010, 7, .   | 0.9 | 0         |
| 323 | Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. <i>Journal of Viral Hepatitis</i> , 2010, 17, 866-871.                                      | 1.0 | 2         |
| 324 | Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.  | 1.4 | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 325 | Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.  | 1.3 | 51        |
| 326 | Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1567-1569.  | 1.3 | 33        |
| 327 | Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.  | 2.9 | 56        |
| 328 | New therapeutic strategies for raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 218-223.   | 1.3 | 11        |
| 329 | European guideline for the management of hepatitis B and C virus infections, 2010. <i>International Journal of STD and AIDS</i> , 2010, 21, 669-678.  | 0.5 | 19        |
| 330 | New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 379-382.   | 1.3 | 10        |
| 331 | Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1493-1496.  | 1.3 | 40        |
| 332 | Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2502-2504.   | 1.3 | 19        |
| 333 | Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 320-326.  | 1.3 | 54        |
| 334 | Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612. | 2.9 | 196       |
| 335 | Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 419-424.   | 0.5 | 6         |
| 336 | Renal toxicity associated with tenofovir use. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 545-559.  | 1.0 | 111       |
| 337 | High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists--authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2057-2058.                           | 1.3 | 0         |
| 338 | Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1647-1649.  | 1.4 | 23        |
| 339 | Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals. <i>Journal of Immunology</i> , 2010, 185, 982-989.   | 0.4 | 38        |
| 340 | Population Pharmacokinetic Modeling of the Association between 63396C>T Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.  | 1.4 | 66        |
| 341 | High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1486-1492.  | 1.3 | 63        |
| 342 | Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 543-547.  | 1.3 | 51        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 343 | Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , 2010, 24, 777-779.  | 1.0 | 11        |
| 344 | Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010, 24, 745-753.   | 1.0 | 32        |
| 345 | Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. <i>Lancet</i> , 2010, 376, 367-387.  | 6.3 | 431       |
| 346 | Prevalence of HTLV-1/2 Infections in Spain: A Cross-Sectional Hospital-Based Survey. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 861-864.  | 0.5 | 15        |
| 347 | The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 242-244.  | 1.0 | 0         |
| 348 | Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 967-972.   | 0.5 | 14        |
| 349 | Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 383-385.  | 0.5 | 9         |
| 350 | Pharmacogenetics of tenofovir treatment. <i>Pharmacogenomics</i> , 2009, 10, 1675-1685.  | 0.6 | 56        |
| 351 | Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1006-1010.  | 1.3 | 64        |
| 352 | Injecting, Sexual Risk Behaviors and HIV Infection in Young Cocaine and Heroin Users in Spain. <i>European Addiction Research</i> , 2009, 15, 171-178.   | 1.3 | 19        |
| 353 | Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4153-4158.  | 1.4 | 6         |
| 354 | Seroprevalence of HTLV-1/2 Infection among Native and Immigrant Pregnant Women in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 551-554.  | 0.5 | 30        |
| 355 | Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. <i>Clinical Infectious Diseases</i> , 2009, 48, e108-e116.  | 2.9 | 221       |
| 356 | HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1615-1629.  | 0.9 | 38        |
| 357 | Update on HIV viral-load assays: new technologies and testing in resource-limited settings. <i>Future Virology</i> , 2009, 4, 423-430.   | 0.9 | 6         |
| 358 | Differences in Lopinavir Plasma Concentrations Comparing Kaletra Film Coated Tablets and Soft Gelatine Capsules That Result in Various Lipid Abnormalities. <i>Drug Metabolism Letters</i> , 2009, 3, 67-69.   | 0.5 | 1         |
| 359 | Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIV-Infected Patient despite Continuous HCV Replication. <i>Clinical Infectious Diseases</i> , 2009, 48, 1634-1635.  | 2.9 | 8         |
| 360 | Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1031-1036. | 1.8 | 66        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 361 | Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 398-410. | 1.3 | 6         |
| 362 | New Therapies for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 313-320.  | 2.9 | 150       |
| 363 | Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1397-1401.  | 2.9 | 35        |
| 364 | Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. <i>Aids</i> , 2009, 23, 689-696.   | 1.0 | 250       |
| 365 | Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009, 81, 763-767.   | 2.5 | 50        |
| 366 | Level, phenotype and activation status of CD4+FoxP3+regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. <i>Clinical and Experimental Immunology</i> , 2009, 155, 35-43.  | 1.1 | 46        |
| 367 | Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 790-795.  | 1.0 | 35        |
| 368 | Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. <i>Journal of Viral Hepatitis</i> , 2009, 16, 895-896.   | 1.0 | 49        |
| 369 | Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 53-59.   | 1.0 | 28        |
| 370 | Clinical Differences and Viral Diversity between Newly HIV Type 1-Diagnosed African and Non-African Patients in Spain (2005-2007). <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 37-44.  | 0.5 | 16        |
| 371 | Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2009, 27, 28-32.  | 0.3 | 3         |
| 372 | Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. <i>Journal of Clinical Virology</i> , 2009, 46, 173-175.   | 1.6 | 30        |
| 373 | Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227.   | 0.5 | 41        |
| 374 | Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1273-1276.   | 0.5 | 295       |
| 375 | The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies. <i>Vaccine</i> , 2009, 27, 2674-2679.   | 1.7 | 3         |
| 376 | 648 DIFFERENCES IN ANTIVIRAL ACTIVITY AND TOLERABILITY BETWEEN PEGYLATED INTERFERON ALPHA 2A AND 2B IN HIV INFECTED PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2009, 50, S238-S239.   | 1.8 | 2         |
| 377 | When and how to use maraviroc in HIV-infected patients. <i>Aids</i> , 2009, 23, 2377-2385.   | 1.0 | 33        |
| 378 | Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. <i>Journal of HIV Therapy</i> , 2009, 14, 13-8.   | 0.6 | 12        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 379 | Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. Journal of Viral Hepatitis, 2008, 15, 165-172.   | 1.0  | 94        |
| 380 | Management of hepatitis B virus co-infection on and off antiretroviral therapy. Current HIV/AIDS Reports, 2008, 5, 86-93.  | 1.1  | 9         |
| 381 | Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools. Journal of Medical Virology, 2008, 80, 383-391.  | 2.5  | 17        |
| 382 | Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8 <sup>+</sup> T cells. European Journal of Immunology, 2008, 38, 1548-1558.  | 1.6  | 14        |
| 383 | Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs, 2008, 13, 1-19.  | 1.0  | 41        |
| 384 | European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Medicine, 2008, 9, 82-88.  | 1.0  | 222       |
| 385 | Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. Journal of Viral Hepatitis, 2008, 15, 363-369.  | 1.0  | 24        |
| 386 | Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. Journal of Viral Hepatitis, 2008, 15, 427-433.  | 1.0  | 87        |
| 387 | Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Journal of Viral Hepatitis, 2008, 15, 710-715.  | 1.0  | 15        |
| 388 | Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 339-354.  | 13.9 | 699       |
| 389 | Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. Journal of Substance Abuse Treatment, 2008, 34, 398-406.  | 1.5  | 12        |
| 390 | Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. Journal of Hepatology, 2008, 49, 323-328.   | 1.8  | 40        |
| 391 | Short Communication:HIV Rebound after Discontinuation of Antiretroviral Therapy Increases and Expands HIV-Specific CD8+Responses But Has No Impact on Its Functionality. AIDS Research and Human Retroviruses, 2008, 24, 1197-1201.  | 0.5  | 6         |
| 392 | Short Communication: Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2008, 24, 389-391.  | 0.5  | 3         |
| 393 | Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 355-365.  | 13.9 | 498       |
| 394 | Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. Journal of Antimicrobial Chemotherapy, 2008, 62, 1365-1373. | 1.3  | 64        |
| 395 | Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. Journal of Antimicrobial Chemotherapy, 2008, 61, 694-698.   | 1.3  | 53        |
| 396 | Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. Journal of Antimicrobial Chemotherapy, 2008, 61, 699-704.   | 1.3  | 87        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 397 | Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 626-627.  | 1.3 | 18        |
| 398 | Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1782-1785.   | 2.9 | 19        |
| 399 | HIV-1 Infection in Persistently HIV-1-Seronegative Individuals: More Reasons for HIV RNA Screening. <i>Clinical Infectious Diseases</i> , 2008, 46, 785-785.  | 2.9 | 6         |
| 400 | Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1-4.   | 1.3 | 249       |
| 401 | Prevalence of and Risk Factors for Hepatitis B Virus Infection among Street-Recruited Young Injection and Non-Injection Heroin Users in Barcelona, Madrid and Seville. <i>European Addiction Research</i> , 2008, 14, 116-124.  | 1.3 | 16        |
| 402 | Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1470-1472.   | 1.3 | 17        |
| 403 | Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. <i>Aids</i> , 2008, 22, 611-616.   | 1.0 | 37        |
| 404 | Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.   | 1.0 | 149       |
| 405 | A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. <i>Aids</i> , 2008, 22, 911-912.  | 1.0 | 12        |
| 406 | Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients. <i>HIV Clinical Trials</i> , 2008, 9, 440-444.   | 2.0 | 13        |
| 407 | Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008. <i>HIV Clinical Trials</i> , 2008, 9, 348-365.  | 2.0 | 1         |
| 408 | No Major Differences in the Functional Profile of HIV Gag and Nef-Specific CD8 <sup>+</sup> Responses between Long-Term Nonprogressors and Typical Progressors. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1185-1195.  | 0.5 | 13        |
| 409 | Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 821-825.   | 0.5 | 39        |
| 410 | Profile of Patients Triply Infected with HIV and the Hepatitis B and C Viruses in the HAART Era. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 679-683.   | 0.5 | 29        |
| 411 | Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 816-822.   | 1.3 | 39        |
| 412 | Hepatitis B virus escape mutants induced by antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 766-768.  | 1.3 | 115       |
| 413 | Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1174-1180.  | 1.3 | 78        |
| 414 | Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2918-2923. | 1.8 | 56        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 415 | Editorial Commentary:Risks and Benefits of Using Antiretroviral Therapy in HIV-Infected Patients with Chronic Hepatitis B in Developing Regions. <i>Clinical Infectious Diseases</i> , 2008, 47, 1486-1489.                                     | 2.9 | 17        |
| 416 | Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.                          | 2.9 | 53        |
| 417 | Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Clinical Microbiology</i> , 2008, 46, 887-891.   | 1.8 | 98        |
| 418 | Management of Chronic Hepatitis C Virus Infection in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2008, 47, 94-101.   | 2.9 | 36        |
| 419 | Reliability of Rapid Subtyping Tools Compared to That of Phylogenetic Analysis for Characterization of Human Immunodeficiency Virus Type 1 Non-B Subtypes and Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3896-3899. | 1.8 | 22        |
| 420 | Increase of Non-B Subtypes and Recombinants Among Newly Diagnosed HIV-1 Native Spaniards and Immigrants in Spain. <i>Current HIV Research</i> , 2008, 6, 327-334.   | 0.2 | 58        |
| 421 | Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.                        | 1.9 | 145       |
| 422 | Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 935-940.   | 0.5 | 20        |
| 423 | Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. <i>Aids</i> , 2008, 22, 2395-2398.  | 1.0 | 30        |
| 424 | Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user. <i>Aids</i> , 2008, 22, 318.   | 1.0 | 3         |
| 425 | Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. <i>Aids</i> , 2008, 22, 1371-1374.   | 1.0 | 2         |
| 426 | Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , 2008, 22, 311-313.   | 1.0 | 8         |
| 427 | Optimal use of maraviroc in clinical practice. <i>Aids</i> , 2008, 22, 2231-2240.   | 1.0 | 33        |
| 428 | Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , 2008, 22, 2535-2537.   | 1.0 | 36        |
| 429 | Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008, 22, 15-21.  | 1.0 | 57        |
| 430 | Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 333-340.   | 0.5 | 17        |
| 431 | Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens. <i>HIV Clinical Trials</i> , 2008, 9, 309-313.  | 2.0 | 10        |
| 432 | Antiretroviral drugs and liver injury. <i>Aids</i> , 2008, 22, 1-13.  | 1.0 | 163       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 433 | Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.  | 1.0 | 43        |
| 434 | Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfecting patients receiving lamivudine as part of antiretroviral therapy. <i>Aids</i> , 2008, 22, 1779-1787.  | 1.0 | 47        |
| 435 | Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1237-1241. | 0.5 | 13        |
| 436 | Short Communication:Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood Cells in Patients during and after Enfuvirtide Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1078-1082.                           | 0.5 | 8         |
| 437 | Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1411-1413.   | 1.3 | 9         |
| 438 | Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205.               | 1.3 | 70        |
| 439 | Amino Acid Conservation in the gp41 Transmembrane Protein and Natural Polymorphisms Associated with Enfuvirtide Resistance across HIV-1 Variants. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1067-1074.                     | 0.5 | 13        |
| 440 | Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 879-885.   | 0.5 | 35        |
| 441 | Escape Mutations in HIV Infection and its Impact on CD8+ T Cell Responses. <i>Current Molecular Medicine</i> , 2007, 7, 446-458.   | 0.6 | 11        |
| 442 | Influence of Human T Cell Lymphotropic Virus Type 2 Coinfection on Virological and Immunological Parameters in HIV Type 1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2007, 44, 105-110.                                    | 2.9 | 16        |
| 443 | Is natural conception a valid option for HIV-serodiscordant couples?. <i>Human Reproduction</i> , 2007, 22, 2353-2358.   | 0.4 | 72        |
| 444 | Drug Interactions of Tipranavir, a New HIV Protease Inhibitor. <i>Drug Metabolism Letters</i> , 2007, 1, 81-84.  | 0.5 | 10        |
| 445 | Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588.  | 1.0 | 24        |
| 446 | Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. <i>Aids</i> , 2007, 21, 1073-1089.   | 1.0 | 295       |
| 447 | Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007, 21, 41-46.   | 1.0 | 127       |
| 448 | Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 839-850.   | 0.9 | 19        |
| 449 | Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 972-982.                               | 0.5 | 183       |
| 450 | Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 891-894.  | 0.5 | 16        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 451 | Liver Fibrosis Stage and HCV Genotype Distribution in HIV/HCV Coinfected Patients with Persistently Normal Transaminases. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 801-804.   | 0.5 | 20        |
| 452 | Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1409-1410.   | 1.3 | 31        |
| 453 | Treatment of Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis. <i>Journal of Infectious Diseases</i> , 2007, 195, 1181-1183.  | 1.9 | 42        |
| 454 | Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, e118-e120. | 2.9 | 17        |
| 455 | Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1). <i>Journal of Clinical Microbiology</i> , 2007, 45, 88-92.  | 1.8 | 24        |
| 456 | Telbivudine: a new option for the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 751-761.  | 1.4 | 35        |
| 457 | CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1141-1147.  | 1.3 | 4         |
| 458 | Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 670-676.  | 1.9 | 157       |
| 459 | Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888.   | 1.3 | 54        |
| 460 | Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.   | 1.3 | 76        |
| 461 | Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 405-410.   | 1.3 | 24        |
| 462 | Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors. <i>Epidemiology and Infection</i> , 2007, 135, 592-603.                               | 1.0 | 21        |
| 463 | Management and therapy of chronic hepatitis C in HIV. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 482-488.   | 1.5 | 1         |
| 464 | Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 802-806.                                    | 1.0 | 28        |
| 465 | Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. <i>Aids</i> , 2007, 21, 1487-1490.   | 1.0 | 42        |
| 466 | Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses. <i>Aids</i> , 2007, 21, 2253-2254.  | 1.0 | 6         |
| 467 | Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. <i>Aids</i> , 2007, 21, 652-653.  | 1.0 | 2         |
| 468 | Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. <i>Aids</i> , 2007, 21, 2521-2527.  | 1.0 | 35        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 469 | Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid. <i>HIV Clinical Trials</i> , 2007, 8, 98-101.  | 2.0 | 20        |
| 470 | Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. <i>Journal of Clinical Virology</i> , 2007, 38, 176-180.  | 1.6 | 24        |
| 471 | Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "ask, draw a blood sample, vaccinate and try to schedule another visit"; <i>Journal of Clinical Virology</i> , 2007, 38, 87-90.  | 1.6 | 13        |
| 472 | Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 679-688.  | 0.9 | 66        |
| 473 | Short Communication: Hospital-Based Surveillance for HTLV-1/2 Infections in Spain. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1075-1077.   | 0.5 | 7         |
| 474 | Value of the HLA-B*5701 Allele to Predict Abacavir Hypersensitivity in Spaniards. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1374-1376.  | 0.5 | 26        |
| 475 | Introduction of Non-B Subtypes among Spaniards Newly Diagnosed with HIV Type 1 in the Canary Islands. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 498-502.  | 0.5 | 20        |
| 476 | Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. <i>European Journal of Immunology</i> , 2007, 37, 501-515.  | 1.6 | 32        |
| 477 | Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. <i>Journal of Medical Virology</i> , 2007, 79, 503-510.  | 2.5 | 26        |
| 478 | Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 1040-1046.  | 2.5 | 43        |
| 479 | Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2007, 7, 382-390.  | 1.0 | 30        |
| 480 | Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , 2007, 54, 173-179.  | 1.7 | 32        |
| 481 | Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. <i>Clinical and Experimental Immunology</i> , 2007, 149, 171-177.   | 1.1 | 12        |
| 482 | Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 387-391.  | 1.0 | 35        |
| 483 | Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 392-395.   | 1.0 | 15        |
| 484 | Evaluation of performance across the dynamic range of the Abbott RealTime <sup>®</sup> HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. <i>Journal of Virological Methods</i> , 2007, 141, 49-57. | 1.0 | 49        |
| 485 | Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1171-1181.  | 1.9 | 25        |
| 486 | Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. <i>Virus Genes</i> , 2007, 34, 111-116.   | 0.7 | 17        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 487 | Update on the treatment of chronic hepatitis C in HIV-infected patients. <i>AIDS Reviews</i> , 2007, 9, 99-113.   | 0.5 | 10        |
| 488 | ¿Se debería recomendar el cribado de la infección por el virus linfotrófico humano de células T de tipo 1 en las mujeres embarazadas?. <i>Progresos En Obstetricia Y Ginecología</i> , 2006, 49, 523-525. | 0.0 | 1         |
| 489 | HTLV infection among young injection and non-injection heroin users in Spain: Prevalence and correlates. <i>Journal of Clinical Virology</i> , 2006, 35, 244-249.   | 1.6 | 29        |
| 490 | Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. <i>Journal of Clinical Virology</i> , 2006, 36, 264-271.            | 1.6 | 55        |
| 491 | Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates. <i>Journal of Hepatology</i> , 2006, 44, S44-S48.  | 1.8 | 22        |
| 492 | Standard of Care for HCV/HIV-Coinfected Patients. <i>Journal of Chemotherapy</i> , 2006, 18, 21-26.   | 0.7 | 0         |
| 493 | Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. <i>Infectious Disorders - Drug Targets</i> , 2006, 6, 57-68.  | 0.4 | 1         |
| 494 | Performance of Six Different Ritonavir-Boosted Protease Inhibitor-Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2006, 7, 163-171.              | 2.0 | 26        |
| 495 | Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. <i>Aids</i> , 2006, 20, 1558-1560.                              | 1.0 | 20        |
| 496 | Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. <i>Aids</i> , 2006, 20, 1951-1954.                                       | 1.0 | 64        |
| 497 | Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. <i>Aids</i> , 2006, 20, 451-453.   | 1.0 | 10        |
| 498 | HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. <i>Aids</i> , 2006, 20, 1359-1367.  | 1.0 | 71        |
| 499 | Mutations affecting the replication capacity of the hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2006, 13, 427-434.   | 1.0 | 109       |
| 500 | Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. <i>Journal of Viral Hepatitis</i> , 2006, 13, 851-857.  | 1.0 | 13        |
| 501 | Overview of the pharmacogenetics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2006, 6, 234-245.  | 0.9 | 55        |
| 502 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199.                                 | 1.2 | 15        |
| 503 | Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. <i>Journal of Medical Virology</i> , 2006, 78, 1599-1608.                                 | 2.5 | 33        |
| 504 | Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , 2006, 20, 1071-1074.   | 1.0 | 29        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 505 | Variability in the P6gag domains of HIV-1 involved in viral budding. <i>Aids</i> , 2006, 20, 624-627.   | 1.0 | 9         |
| 506 | Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 154-159.  | 0.9 | 18        |
| 507 | Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity. <i>HIV Clinical Trials</i> , 2006, 7, 246-250.   | 2.0 | 26        |
| 508 | Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. <i>Aids</i> , 2006, 20, 1460-1462.  | 1.0 | 23        |
| 509 | Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 1092-1097.   | 1.5 | 15        |
| 510 | Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1. <i>Clinical Infectious Diseases</i> , 2006, 42, 291-295.  | 2.9 | 116       |
| 511 | Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 806-809.  | 1.3 | 33        |
| 512 | Can the Level of Immunosuppression in Human Immunodeficiency Virus-Infected Patients Affect the Reliability of Human T-Cell Lymphotropic Virus Type 2 Serological Diagnosis?. <i>Vaccine Journal</i> , 2006, 13, 160-161.                           | 3.2 | 7         |
| 513 | HIV entry inhibitors: mechanisms of action and resistance pathways. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 619-627.   | 1.3 | 156       |
| 514 | Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2006, 43, 1209-1212.  | 2.9 | 36        |
| 515 | Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges. <i>Journal of Infectious Diseases</i> , 2006, 194, 904-911. | 1.9 | 185       |
| 516 | Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 694-701.   | 1.4 | 78        |
| 517 | Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 537-542.          | 2.0 | 32        |
| 518 | Management of chronic hepatitis B and C in HIV-coinfecting patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 815-818.  | 1.3 | 78        |
| 519 | Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 709-713.   | 1.3 | 79        |
| 520 | Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. <i>Clinical Infectious Diseases</i> , 2006, 42, 1032-1039.             | 2.9 | 51        |
| 521 | New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 550-560.  | 1.3 | 15        |
| 522 | Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfecting Population Followed at a Reference HIV Center. <i>HIV Clinical Trials</i> , 2005, 6, 329-336.   | 2.0 | 23        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 523 | Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.   | 1.0 | 75        |
| 524 | Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity. <i>HIV Clinical Trials</i> , 2005, 6, 197-202.   | 2.0 | 28        |
| 525 | HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. <i>HIV Medicine</i> , 2005, 6, 313-320.   | 1.0 | 46        |
| 526 | Clinical benefit of interventions driven by therapeutic drug monitoring. <i>HIV Medicine</i> , 2005, 6, 360-365.   | 1.0 | 32        |
| 527 | Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. <i>Haemophilia</i> , 2005, 11, 433-437.  | 1.0 | 9         |
| 528 | Natural history of Hymenoptera venom allergy in Eastern Spain. <i>Clinical and Experimental Allergy</i> , 2005, 35, 179-185.   | 1.4 | 29        |
| 529 | Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. <i>Journal of Virological Methods</i> , 2005, 127, 54-59.  | 1.0 | 42        |
| 530 | Heterogeneous nature of HIV-1 recombinants spreading in Spain. <i>Journal of Medical Virology</i> , 2005, 75, 374-380.   | 2.5 | 23        |
| 531 | Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005, 76, 1-6.  | 2.5 | 8         |
| 532 | Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. <i>Journal of Medical Virology</i> , 2005, 76, 268-270.   | 2.5 | 27        |
| 533 | Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 23-28.   | 2.5 | 23        |
| 534 | Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 460-464.  | 2.5 | 21        |
| 535 | Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. <i>PLoS Medicine</i> , 2005, 2, e112.  | 3.9 | 262       |
| 536 | Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3997-4008. | 1.4 | 42        |
| 537 | Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354.   | 2.9 | 53        |
| 538 | Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232.   | 2.9 | 31        |
| 539 | Viral Response to Antiretroviral Therapy in a Patient Coinfected with HIV Type 1 and Type 2. <i>Clinical Infectious Diseases</i> , 2005, 41, e19-e21.  | 2.9 | 19        |
| 540 | Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption. <i>Clinical Infectious Diseases</i> , 2005, 41, 897-900.   | 2.9 | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 541 | Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.   | 1.9 | 385       |
| 542 | Failure of Hepatitis C Therapy in HIV-Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype. <i>Journal of Infectious Diseases</i> , 2005, 192, 1245-1248.  | 1.9 | 8         |
| 543 | Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3860-3868. | 1.8 | 103       |
| 544 | Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.  | 2.9 | 197       |
| 545 | CD4+T Cell Recovery beyond the First Year of Complete Suppression of Viral Replication during Highly Active Antiretroviral Therapy Is Not Influenced by CD8+T Cell Activation. <i>Journal of Infectious Diseases</i> , 2005, 192, 2142-2146.  | 1.9 | 20        |
| 546 | Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors. <i>HIV Clinical Trials</i> , 2005, 6, 50-61.   | 2.0 | 5         |
| 547 | Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin. <i>HIV Clinical Trials</i> , 2005, 6, 278-280.  | 2.0 | 15        |
| 548 | Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. <i>Aids</i> , 2005, 19, 2036-2038.  | 1.0 | 46        |
| 549 | Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125.  | 1.0 | 109       |
| 550 | Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2005, 19, 621-623.  | 1.0 | 8         |
| 551 | Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B. <i>HIV Clinical Trials</i> , 2005, 6, 103-106.   | 2.0 | 7         |
| 552 | Management of patients co-infected with hepatitis B virus and HIV. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 374-382.   | 4.6 | 63        |
| 553 | Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2831-2842.  | 0.9 | 2         |
| 554 | Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2005, 40, 1358-1361.   | 2.9 | 176       |
| 555 | Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.  | 1.9 | 362       |
| 556 | Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2005, 42, 290-292.   | 1.8 | 12        |
| 557 | Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients. <i>Journal of Clinical Virology</i> , 2005, 32, 338-339.   | 1.6 | 6         |
| 558 | Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. <i>Journal of Clinical Virology</i> , 2005, 33, 65-70.  | 1.6 | 15        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 559 | Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. <i>Journal of Clinical Virology</i> , 2005, 34, 295-301.   | 1.6 | 55        |
| 560 | Hepatotoxicity of Antiretrovirals. <i>Drug Safety</i> , 2005, 28, 53-66.   | 1.4 | 91        |
| 561 | Phage Display Selection of HIV Specific Conserved Mimotopes With IgG from Long-term Non-progressors. <i>Retrovirology</i> , 2005, 2, P29.  | 0.9 | 0         |
| 562 | Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. <i>Aids</i> , 2005, 19, 221-40.   | 1.0 | 49        |
| 563 | Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 275-278.  | 0.5 | 59        |
| 564 | CD38 Expression on CD8 T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 227-233.       | 0.5 | 80        |
| 565 | Are Fusion Inhibitors Active against All HIV Variants?. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 347-348.   | 0.5 | 51        |
| 566 | Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1026-1031.      | 0.5 | 32        |
| 567 | Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 128-133.       | 2.9 | 291       |
| 568 | Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes. <i>Clinical Infectious Diseases</i> , 2004, 39, 1231-1238.  | 2.9 | 32        |
| 569 | Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations. <i>Journal of Clinical Microbiology</i> , 2004, 42, 862-866. | 1.8 | 2         |
| 570 | Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz. <i>Clinical Infectious Diseases</i> , 2004, 38, 430-432.  | 2.9 | 128       |
| 571 | Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. <i>Intervirology</i> , 2004, 47, 350-354.                 | 1.2 | 3         |
| 572 | Impact of Chronic Hepatitis C on HIV-1 Disease Progression. <i>HIV Clinical Trials</i> , 2004, 5, 125-131.   | 2.0 | 44        |
| 573 | How effective is HAART in HCV and HIV coinfection?. <i>Aids</i> , 2004, 18, 2081-2084.   | 1.0 | 6         |
| 574 | Hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2004, 18, 2285-2293.  | 1.0 | 213       |
| 575 | HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. <i>Aids</i> , 2004, 18, 495-502.  | 1.0 | 39        |
| 576 | Short Communication: Liver Toxicity of Lopinavir-Containing Regimens in HIV-Infected Patients with or without Hepatitis C Coinfection. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 698-700.                      | 0.5 | 44        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 577 | Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 351-353.   | 0.5 | 42        |
| 578 | Changes in Mitochondrial DNA Copy Number in Blood Cells from HIV-Infected Patients Undergoing Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 271-273.   | 0.5 | 41        |
| 579 | Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004, 121, 115-118. | 1.0 | 25        |
| 580 | Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004, 11, 2-17.  | 1.0 | 65        |
| 581 | Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. <i>Journal of Medical Virology</i> , 2004, 74, 21-28.                                       | 2.5 | 64        |
| 582 | Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. <i>Journal of Medical Virology</i> , 2004, 74, 521-527.  | 2.5 | 47        |
| 583 | Management of Chronic Hepatitis C in Patients Co-Infected with HIV. <i>Drug Safety</i> , 2004, 27, 7-24.   | 1.4 | 13        |
| 584 | Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. <i>Journal of Clinical Virology</i> , 2004, 31, 215-220.                          | 1.6 | 56        |
| 585 | Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.                      | 6.3 | 303       |
| 586 | Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , 2004, 18, 689-690.  | 1.0 | 4         |
| 587 | Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. <i>Aids</i> , 2004, 18, 1251-1261.  | 1.0 | 11        |
| 588 | Reply to Bruno et al.. <i>Aids</i> , 2004, 18, 2102-2103.  | 1.0 | 0         |
| 589 | New Hopes for HIV and HCV Coinfection in 2004. <i>HIV Clinical Trials</i> , 2004, 5, 232-251.  | 2.0 | 9         |
| 590 | Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. <i>Aids</i> , 2004, 18, 2091-2094.   | 1.0 | 16        |
| 591 | Tenofovir-related nephrotoxicity in HIV-infected patients. <i>Aids</i> , 2004, 18, 960-963.  | 1.0 | 96        |
| 592 | Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. <i>Aids</i> , 2004, 18, 1137-1146.  | 1.0 | 64        |
| 593 | Predictors of selection of K65R. <i>Aids</i> , 2004, 18, 2094-2096.  | 1.0 | 36        |
| 594 | Care of patients with hepatitis C and HIV co-infection. <i>Aids</i> , 2004, 18, 1-12.  | 1.0 | 194       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 595 | Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. <i>Aids</i> , 2004, 18, 1109-1116.   | 1.0 | 93        |
| 596 | Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients. <i>HIV Clinical Trials</i> , 2004, 5, 201-205.   | 2.0 | 66        |
| 597 | Resistance to HIV Protease Inhibitors: Mechanisms and Clinical Consequences. <i>Current Drug Metabolism</i> , 2004, 5, 321-328.   | 0.7 | 29        |
| 598 | Performance of drug resistance assays in testing HIV-1 non-B subtypes. <i>Clinical Microbiology and Infection</i> , 2003, 9, 323-326.   | 2.8 | 12        |
| 599 | Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. <i>Clinical Microbiology and Infection</i> , 2003, 9, 422-425.   | 2.8 | 12        |
| 600 | Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon $\alpha$ -2b Plus Ribavirin. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1083-1089.   | 0.5 | 25        |
| 601 | Distribution of Hepatitis B Virus Genotypes in HIV-Infected Patients with Chronic Hepatitis B: Therapeutic Implications. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 657-659.                                 | 0.5 | 34        |
| 602 | Short Communication: Interactions between Nevirapine Plasma Levels, Chronic Hepatitis C, and the Development of Liver Toxicity in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 187-188. | 0.5 | 31        |
| 603 | Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 457-459.   | 0.5 | 13        |
| 604 | Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1245-1247.   | 1.8 | 33        |
| 605 | Treatment of Chronic Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Present and Future. <i>Clinical Infectious Diseases</i> , 2003, 37, 1678-1685.   | 2.9 | 56        |
| 606 | Impact of Hepatitis C Virus (HCV) on Morbidity and Mortality Rates among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2003, 37, 460-461.  | 2.9 | 3         |
| 607 | Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 363-368.                      | 0.5 | 14        |
| 608 | SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1079-1082.                                  | 0.5 | 7         |
| 609 | Gynecomastia in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 739-741.  | 0.5 | 12        |
| 610 | Transmission of HIV Type 1 through Blood Transfusion from an Antibody-Negative/p24 Antigen-Negative Donor. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 447-448.   | 0.5 | 4         |
| 611 | Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4421-4423.                       | 1.8 | 11        |
| 612 | First-Line Therapy and Mitochondrial Damage: Different Nucleosides, Different Findings. <i>HIV Clinical Trials</i> , 2003, 4, 11-19.  | 2.0 | 31        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 613 | Pegylated IFN- $\alpha$ 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003, 17, 1023-1028.   | 1.0  | 183       |
| 614 | Hepatitis B Virus Infection Despite Receiving Lamivudine in One HIV-Infected Person. <i>HIV Clinical Trials</i> , 2003, 4, 77-78.   | 2.0  | 4         |
| 615 | HIV-Positive Immigrants in the Canary Islands, Spain: Implications for Public Health in Europe. <i>HIV Clinical Trials</i> , 2003, 4, 184-192.  | 2.0  | 16        |
| 616 | Replacement of Protease Inhibitors by Nevirapine or Efavirenz in Simplification and Rescue Interventions: Which Works Better?. <i>HIV Clinical Trials</i> , 2003, 4, 244-247.   | 2.0  | 3         |
| 617 | Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.  | 13.9 | 1,560     |
| 618 | Hydroxyurea plus Didanosine as Maintenance Therapy for HIV-Infected Patients on Long-Term Successful Highly Active Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2003, 4, 361-371.                                     | 2.0  | 16        |
| 619 | Avascular Necrosis in HIV-Infected Patients Receiving Antiretroviral Treatment: Study of Seven Cases. <i>HIV Clinical Trials</i> , 2003, 4, 132-136.  | 2.0  | 21        |
| 620 | Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine. <i>HIV Clinical Trials</i> , 2003, 4, 115-120.   | 2.0  | 106       |
| 621 | Long-Term Outcome of HIV-Infected Patients with Multinucleoside-Resistant Genotypes. <i>HIV Clinical Trials</i> , 2003, 4, 372-381.   | 2.0  | 7         |
| 622 | Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus Type I from a single donor. <i>Transplantation</i> , 2003, 75, 102-104.                   | 0.5  | 116       |
| 623 | Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. <i>Aids</i> , 2003, 17, 442-444.  | 1.0  | 4         |
| 624 | Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. <i>Aids</i> , 2003, 17, 919-921.   | 1.0  | 4         |
| 625 | Replacing stavudine by abacavir reduces lactate levels and may improve lipotrophy. <i>Aids</i> , 2003, 17, 921-924.   | 1.0  | 18        |
| 626 | Toxicidad mitocondrial de los antirretrovirales: diagnóstico y monitorización. <i>Medicina Clínica</i> , 2003, 121, 310-315.  | 0.3  | 5         |
| 627 | HIV-1 Subtype J Recombinant Viruses in Spain. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 523-529.  | 0.5  | 10        |
| 628 | Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1379-1388. | 0.5  | 34        |
| 629 | Prevalence of the HIV Protease Mutation N88S Causing Hypersensitivity to Amprenavir. <i>Clinical Infectious Diseases</i> , 2002, 34, 1288-1289.   | 2.9  | 4         |
| 630 | Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 857-860.   | 0.5  | 19        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 631 | Hcv Chronic Hepatitis in Patients With Hiv: Clinical Management Issues. American Journal of Gastroenterology, 2002, 97, 1598-1606.   | 0.2 | 25        |
| 632 | Rapid Assessment of Phenotypic Resistance to Protease Inhibitors in Human Immunodeficiency Virus Type 1 Group O. Journal of Clinical Microbiology, 2002, 40, 4313-4316.  | 1.8 | 4         |
| 633 | Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sexually Transmitted Infections, 2002, 78, 255-260.   | 0.8 | 20        |
| 634 | Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clinical Trials, 2002, 3, 237-248.   | 2.0 | 32        |
| 635 | Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?. HIV Clinical Trials, 2002, 3, 463-467.  | 2.0 | 9         |
| 636 | High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. Aids, 2002, 16, 1163-1170.  | 1.0 | 61        |
| 637 | Resistance to Antiretroviral Agents in Individuals with HIV-1 Non-B Subtypes. HIV Clinical Trials, 2002, 3, 403-411.   | 2.0 | 32        |
| 638 | Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. Journal of Clinical Microbiology, 2002, 40, 3865-3866. | 1.8 | 30        |
| 639 | Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. Journal of Clinical Microbiology, 2002, 40, 1518-1521.  | 1.8 | 28        |
| 640 | Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons. HIV Clinical Trials, 2002, 3, 351-353.  | 2.0 | 6         |
| 641 | Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. Aids, 2002, 16, 245-249.  | 1.0 | 57        |
| 642 | Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV and HCV International Panel. Aids, 2002, 16, 813-828.   | 1.0 | 280       |
| 643 | Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clinical Trials, 2002, 3, 249-257.   | 2.0 | 9         |
| 644 | Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. HIV Clinical Trials, 2002, 3, 9-16.   | 2.0 | 18        |
| 645 | Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families. HIV Clinical Trials, 2002, 3, 304-309.   | 2.0 | 40        |
| 646 | SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. HIV Clinical Trials, 2002, 3, 186-194.   | 2.0 | 58        |
| 647 | Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. HIV Clinical Trials, 2002, 3, 99-114.  | 2.0 | 23        |
| 648 | Infection with Retroviruses Other Than HIV-1 in Spain: A Retrospective Analysis for HIV-2, HTLV-I, and/or HTLV-II. HIV Clinical Trials, 2002, 3, 397-402.  | 2.0 | 10        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 649 | Cryptosporidiosis. <i>New England Journal of Medicine</i> , 2002, 347, 1287-1287.  | 13.9 | 38        |
| 650 | Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 438-443.        | 1.1  | 41        |
| 651 | Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in HIV-infected patients. <i>Journal of Hepatology</i> , 2002, 36, 107.  | 1.8  | 0         |
| 652 | Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 108.                                       | 1.8  | 0         |
| 653 | Motivo de ingreso hospitalario en pacientes con infección por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. <i>Medicina Clínica</i> , 2002, 119, 293-295. | 0.3  | 3         |
| 654 | A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. <i>HIV Medicine</i> , 2002, 3, 229-238.  | 1.0  | 12        |
| 655 | Liver toxicity caused by nevirapine. <i>Aids</i> , 2002, 16, 290-291.  | 1.0  | 151       |
| 656 | Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. <i>Aids</i> , 2002, 16, 493-495.                                    | 1.0  | 15        |
| 657 | Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. <i>Aids</i> , 2002, 16, 1087-1089.  | 1.0  | 9         |
| 658 | Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. <i>Aids</i> , 2002, 16, 1423-1425.                                    | 1.0  | 31        |
| 659 | Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. <i>Aids</i> , 2002, 16, 1830-1832.   | 1.0  | 26        |
| 660 | Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. <i>Aids</i> , 2002, 16, 1959-1961.   | 1.0  | 51        |
| 661 | Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. <i>Aids</i> , 2002, 16, 1964-1966.  | 1.0  | 31        |
| 662 | Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. <i>Aids</i> , 2002, 16, 2079-2081.  | 1.0  | 48        |
| 663 | Lack of "occult" hepatitis B virus infection in HIV-infected patients. <i>Aids</i> , 2002, 16, 2099-2101.  | 1.0  | 72        |
| 664 | Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. <i>Aids</i> , 2002, 16, 2352-2354.   | 1.0  | 101       |
| 665 | Genetic mechanisms of resistance to NRTI and NNRTI. <i>HIV Clinical Trials</i> , 2002, 3, 237-48.  | 2.0  | 15        |
| 666 | Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. <i>HIV Clinical Trials</i> , 2002, 3, 249-57.  | 2.0  | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 667 | Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.  | 0.2 | 62        |
| 668 | Response to Drs. Toyoda et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 3441-3442.  | 0.2 | 0         |
| 669 | The effect of antiretroviral therapy on HTLV infection. <i>Virus Research</i> , 2001, 78, 93-100.   | 1.1 | 48        |
| 670 | Prevalence and Genetic Heterogeneity of the Reverse Transcriptase T69S-S-X Insertion in Pretreated HIV-Infected Patients. <i>Intervirology</i> , 2001, 44, 339-343.   | 1.2 | 10        |
| 671 | Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , 2001, 15, 1701-1706.   | 1.0 | 61        |
| 672 | Role of Nonnucleosides in the Development of HAART-Related Lipid Disturbances. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 496-498.   | 0.9 | 6         |
| 673 | Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. <i>Clinical Microbiology and Infection</i> , 2001, 7, 678-681.   | 2.8 | 16        |
| 674 | Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. <i>Journal of Medical Virology</i> , 2001, 64, 217-222.   | 2.5 | 10        |
| 675 | Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. <i>Journal of Medical Virology</i> , 2001, 63, 85-87.  | 2.5 | 17        |
| 676 | Management of hepatitis C in HIV-infected persons. <i>Antiviral Research</i> , 2001, 52, 189-198.   | 1.9 | 28        |
| 677 | Intensification of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 499-506.   | 0.5 | 5         |
| 678 | Comparative Performance of Three Viral Load Assays on Human Immunodeficiency Virus Type 1 (HIV-1) Isolates Representing Group M (Subtypes A to G) and Group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR Version 1.5, and Quantiplex HIV-1 RNA Version 3.0. <i>Journal of Clinical Microbiology</i> , 2001, 39, 862-870. | 1.8 | 54        |
| 679 | Primary lymphoma of the central nervous system and HTLV-I infection. <i>Haematologia</i> , 2001, 31, 365-367.   | 0.2 | 12        |
| 680 | Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. <i>Aids</i> , 2001, 15, 309-320.   | 1.0 | 169       |
| 681 | Sequencing antiretroviral drugs. <i>Aids</i> , 2001, 15, 547-551.   | 1.0 | 13        |
| 682 | Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1467-1471.   | 0.5 | 197       |
| 683 | Molecular Evidence of Homosexual Transmission of HIV Type 2 in Spain. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 417-422.  | 0.5 | 21        |
| 684 | Response to Drs. Toyoda et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 3441-3442.  | 0.2 | 1         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 685 | Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.   | 0.2 | 215       |
| 686 | Prevalence of Human Immunodeficiency Virus Type 1 (HIV-1) Non-B Subtypes in Foreigners Living in Madrid, Spain, and Comparison of the Performances of the AMPLICOR HIV-1 MONITOR Version 1.0 and the New Automated Version 1.5. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1850-1854. | 1.8 | 34        |
| 687 | Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 33, 1793-1795.   | 2.9 | 46        |
| 688 | Naturally Occurring Sequence Polymorphisms within HIV Type 1 Group O Protease. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1555-1561.  | 0.5 | 25        |
| 689 | Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. <i>Aids</i> , 2001, 15, 1894-1896.   | 1.0 | 37        |
| 690 | Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine. <i>Aids</i> , 2001, 15, 2469-2470.   | 1.0 | 4         |
| 691 | Protease sequences from HIV-1 group M subtypes A??H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. <i>Aids</i> , 2000, 14, 1489-1495.   | 1.0 | 125       |
| 692 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. <i>Aids</i> , 2000, 14, 2153-2157.  | 1.0 | 74        |
| 693 | Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 383-386.  | 1.0 | 109       |
| 694 | Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. <i>Aids</i> , 2000, 14, 913-919.   | 1.0 | 20        |
| 695 | Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. , 2000, 61, 111-116.   |     | 89        |
| 696 | Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. <i>Journal of Viral Hepatitis</i> , 2000, 7, 403-408.   | 1.0 | 34        |
| 697 | Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. <i>EMBO Journal</i> , 2000, 19, 5752-5761.   | 3.5 | 100       |
| 698 | Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. <i>Aids</i> , 2000, 14, 727-732.  | 1.0 | 53        |
| 699 | Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. <i>Aids</i> , 2000, 14, 807-812.   | 1.0 | 143       |
| 700 | Protease Gene Analysis of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1395-1403.   | 0.5 | 30        |
| 701 | Prevalence of HTLV infection in pregnant women in Spain. <i>Sexually Transmitted Infections</i> , 2000, 76, 366-370.   | 0.8 | 37        |
| 702 | Is there a role for indinavir twice-daily in clinical practice?. <i>Clinical Microbiology and Infection</i> , 2000, 6, 152-154.  | 2.8 | 1         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 703 | Tolerability of Abacavir in the clinical setting. <i>Clinical Microbiology and Infection</i> , 2000, 6, 621-622.  | 2.8 | 0         |
| 704 | Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. <i>Virus Research</i> , 2000, 66, 13-26.   | 1.1 | 34        |
| 705 | Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. <i>Medicina Clínica</i> , 2000, 115, 118.   | 0.3 | 2         |
| 706 | Recombinant Human Immunodeficiency Viruses Type 1 Circulating in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 505-511.  | 0.5 | 29        |
| 707 | Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 207.   | 1.0 | 4         |
| 708 | Hepatitis C viraemia in HIV/HCV co-infected patients having immune restoration with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 212.  | 1.0 | 61        |
| 709 | Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. <i>Aids</i> , 2000, 14, 1659-1660.   | 1.0 | 5         |
| 710 | Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. <i>Aids</i> , 2000, 14, 1672-1673.   | 1.0 | 25        |
| 711 | Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2000, 14, 2409-2410.  | 1.0 | 8         |
| 712 | Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1370-1374.                     | 1.8 | 81        |
| 713 | Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. <i>Journal of Medical Virology</i> , 2000, 61, 111-6.                       | 2.5 | 32        |
| 714 | Human Immunodeficiency Virus Type 2 Infection in Spain. <i>Intervirology</i> , 1999, 42, 37-42.   | 1.2 | 17        |
| 715 | CCR5 genotype and HIV-1 infection in perinatally-exposed infants. <i>Journal of Infection</i> , 1999, 38, 9-11.   | 1.7 | 10        |
| 716 | CCR5 Genotype and Human Immunodeficiency Virus Type 1 Infection in Perinatally Exposed Infants. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 389-391.                         | 1.3 | 3         |
| 717 | Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. <i>European Journal of Epidemiology</i> , 1999, 15, 1-4.                                | 2.5 | 158       |
| 718 | Human T-cell Leukemia/Lymphoma Virus Type II Infection in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 75-76.  | 1.3 | 5         |
| 719 | Association Between Submaximal Suppression of HIV Replication and Use of Drug Combinations Without Protease Inhibitors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 604-605. | 1.3 | 0         |
| 720 | Diabetes Mellitus Associated with Protease Inhibitor Use. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 675-677.   | 1.3 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 721 | Human immunodeficiency viruses type 1 subtypes circulating in Spain. <i>Journal of Medical Virology</i> , 1999, 59, 189-193.   | 2.5 | 18        |
| 722 | Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. <i>Journal of Hepatology</i> , 1999, 31, 119-123.   | 1.8 | 61        |
| 723 | Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 769-773.   | 0.5 | 11        |
| 724 | Higher antiviral activity of antiretroviral regimens including protease inhibitors. <i>Aids</i> , 1999, 13, 998.   | 1.0 | 8         |
| 725 | Introduction of HIV drug-resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1007-1014.   | 1.0 | 62        |
| 726 | Management of chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 1999, 13, 539-546.   | 1.0 | 90        |
| 727 | Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. <i>Aids</i> , 1999, 13, 1763-1769.   | 1.0 | 540       |
| 728 | Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. <i>Aids</i> , 1999, 13, 524.   | 1.0 | 26        |
| 729 | Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. <i>Aids</i> , 1999, 13, 525.  | 1.0 | 25        |
| 730 | V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection. <i>Aids</i> , 1999, 13, 532.  | 1.0 | 5         |
| 731 | Spanish consensus conference on drug resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1998.  | 1.0 | 15        |
| 732 | What dual protease inhibitor combination for salvage therapies?. <i>Aids</i> , 1999, 13, 2180.   | 1.0 | 9         |
| 733 | A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC). <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 264-270. | 1.4 | 28        |
| 734 | Detection of HTLV-II proviral sequences in HIV-immunosuppressed patients with HTLV indeterminate serological patterns. <i>Journal of Infection</i> , 1998, 36, 243-244.  | 1.7 | 6         |
| 735 | The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. <i>Journal of Infection</i> , 1998, 36, 307-311.                                      | 1.7 | 20        |
| 736 | LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. <i>Virus Research</i> , 1998, 57, 11-20.  | 1.1 | 27        |
| 737 | Lack of benefit or protease inhibitors on HCV viremia in HIV- infected patients. <i>Journal of Hepatology</i> , 1998, 28, 526-527.   | 1.8 | 52        |
| 738 | Evidence of Nef Truncation in Human Immunodeficiency Virus Type 2 Infection. <i>Journal of Infectious Diseases</i> , 1998, 177, 65-71.   | 1.9 | 31        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 739 | Regression of Invasive AIDS-Related Kaposi's Sarcoma Following Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1998, 26, 218-219.  | 2.9 | 20        |
| 740 | Horizontal and Vertical Transmission of Human Immunodeficiency Virus Type 1 Dual Infections Caused by Viruses of Subtypes B and C. <i>Journal of Infectious Diseases</i> , 1998, 177, 227-231.                     | 1.9 | 48        |
| 741 | <b>Sequence Note</b>: Genetic Analysis of Human Immunodeficiency Virus Type 2 Strains from Spain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 91-94.   | 0.5 | 2         |
| 742 | Letter to the Editor: Phylogenetic Analysis of HIV Type 2 Strains from Portugal. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 471-473.  | 0.5 | 5         |
| 743 | Tropism, Coreceptor Use, and Phylogenetic Analysis of Both the V3 Loop and the Protease Gene of Three Novel HIV-1 Group O Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 417-425.    | 0.3 | 9         |
| 744 | False positives for HIV using commercial viral load quantification assays. <i>Aids</i> , 1998, 12, 2076-2077.  | 1.0 | 18        |
| 745 | Hepatotoxicity after introduction of highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1256.   | 1.0 | 180       |
| 746 | Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015. | 1.5 | 64        |
| 747 | Opportunistic Infections Shortly after Beginning Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 1998, 3, 229-231.  | 0.6 | 29        |
| 748 | Chemokine receptors and HIV-2. <i>Aids</i> , 1997, 11, 1198-1199.  | 1.0 | 22        |
| 749 | Evidence of HIV-2 Infection in Equatorial Guinea (Central Africa): Partial Genetic Analysis of a B Subtype Virus. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 439-440.                                 | 0.5 | 9         |
| 750 | Genetic Analysis of an HIV Type 2 Subtype B Virus from a Spanish Individual with AIDS. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 899-900.  | 0.5 | 5         |
| 751 | Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. <i>Transfusion Science</i> , 1997, 18, 63-69.                       | 0.6 | 10        |
| 752 | Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C. <i>Journal of Infection</i> , 1997, 35, 202-203.   | 1.7 | 1         |
| 753 | Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate. <i>Virology</i> , 1997, 236, 364-373.  | 1.1 | 60        |
| 754 | A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1997, 35, 225-230.  | 1.7 | 15        |
| 755 | Hepatitis C Virus Genotypes 1a and 1b Mixed Infections. <i>Vox Sanguinis</i> , 1997, 72, 64-64.  | 0.7 | 0         |
| 756 | Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. <i>British Journal of Haematology</i> , 1997, 98, 927-933.   | 1.2 | 65        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 757 | Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir. <i>Aids</i> , 1997, 11, 1896-1897.                         | 1.0 | 3         |
| 758 | Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. <i>Clinical and Diagnostic Virology</i> , 1996, 7, 85-92.                              | 1.8 | 26        |
| 759 | First Case of HIV-1 Group O Infection in Spain. <i>Vox Sanguinis</i> , 1996, 71, 66-66.  | 0.7 | 34        |
| 760 | Hepatitis C viraemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 922.  | 1.0 | 8         |
| 761 | High Rate of Indeterminate Reactivity to HTLV in Western Blot Analysis of Spanish Blood Donors. <i>Vox Sanguinis</i> , 1996, 70, 120-121.  | 0.7 | 7         |
| 762 | Circulating Hepatitis C Virus Genotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 180-181.  | 0.7 | 10        |
| 763 | Circulating HIV-1 Serotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 236-237.  | 0.7 | 2         |
| 764 | Correlation between Serological and Genetic Methods for Typing Hepatitis C Virus. <i>Vox Sanguinis</i> , 1996, 71, 190-191.  | 0.7 | 3         |
| 765 | Sexual Transmission of Two Different HCV Types Causing Acute Hepatitis C. <i>Vox Sanguinis</i> , 1996, 71, 244-245.  | 0.7 | 7         |
| 766 | Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. <i>European Journal of Epidemiology</i> , 1996, 12, 625-629.  | 2.5 | 12        |
| 767 | Interferon $\alpha$ for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 23, 585-591.                                      | 2.9 | 187       |
| 768 | Epidemiology of HTLV-I Infection in Spain. <i>International Journal of Epidemiology</i> , 1996, 25, 443-449.   | 0.9 | 10        |
| 769 | Sequence Note: env Gene Characterization of the First HIV Type 1 Group O Spanish Isolate. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1647-1649.   | 0.5 | 21        |
| 770 | Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 955-957.  | 0.5 | 8         |
| 771 | Serial Dilutions on Synthetic Peptide-Based Assays Can Resolve Dual Seroreactivity to HIV-1 and HIV-2. <i>Vox Sanguinis</i> , 1996, 71, 67-68.   | 0.7 | 5         |
| 772 | Efficacy and safety of $\alpha$ -interferon treatment for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1995, 31, 9-13.  | 1.7 | 45        |
| 773 | Ion-pair reversed-phase and low-molecular-weight aqueous gel permeation high-performance liquid chromatography methods for the determination of amoxicillin oligomers. <i>Chromatographia</i> , 1995, 41, 651-656. | 0.7 | 7         |
| 774 | Avoiding false-negative results for HTLV-II using new serological assays. <i>American Journal of Medicine</i> , 1995, 98, 103.   | 0.6 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 775 | High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. <i>Journal of Hepatology</i> , 1995, 22, 598-599.  | 1.8 | 15        |
| 776 | Sequence Analysis of the V1/V2 and V3 Domains in an HIV-Seronegative AIDS Patient. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1539-1541.   | 0.5 | 3         |
| 777 | Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1735-1738. | 1.8 | 19        |
| 778 | Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. <i>Journal of Virology</i> , 1995, 69, 621-632.   | 1.5 | 98        |
| 779 | Gastrointestinal Leishmaniasis in Human Immunodeficiency Virus-Infected Patients: Report of Five Cases and Review. <i>Clinical Infectious Diseases</i> , 1994, 19, 48-53.   | 2.9 | 96        |
| 780 | Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. <i>Journal of Infection</i> , 1994, 28, 255-259.   | 1.7 | 25        |
| 781 | High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. <i>Journal of Infection</i> , 1994, 28, 100-102.  | 1.7 | 17        |
| 782 | Significance of HCV RIBA Indeterminate Results in High-Risk Individuals: Assessment by a New Third-Generation RIBA Assay and PCR. <i>Vox Sanguinis</i> , 1994, 66, 148-149.   | 0.7 | 9         |
| 783 | Evaluation of a New Saliva Collection Device for HIV Antibody Screening Purposes. <i>Vox Sanguinis</i> , 1994, 66, 244-244.   | 0.7 | 7         |
| 784 | HIV-1 Causing AIDS and Death in a Seronegative Individual. <i>Vox Sanguinis</i> , 1994, 67, 410-411.  | 0.7 | 46        |
| 785 | Seroreversion in Patients with End-Stage HIV Infection. <i>Vox Sanguinis</i> , 1994, 67, 238-239.   | 0.7 | 21        |
| 786 | HTLV-II Infection among Immigrants to Spain. <i>Vox Sanguinis</i> , 1994, 67, 79-80.  | 0.7 | 4         |
| 787 | Evaluation of a New Fluorescence Immunoassay for CD4+ and CD8+ T Cell Counts in Clinical Samples. <i>Vox Sanguinis</i> , 1994, 67, 86-87.   | 0.7 | 5         |
| 788 | Idiopathic CD4+ T Lymphocytopenia: A Review and Current Perspective. <i>Transfusion Medicine Reviews</i> , 1994, 8, 223-231.  | 0.9 | 4         |
| 789 | Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2. <i>Journal of Virological Methods</i> , 1994, 49, 37-46.  | 1.0 | 14        |
| 790 | CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. <i>Aids</i> , 1994, 8, 1621.  | 1.0 | 48        |
| 791 | Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome. <i>Aids</i> , 1994, 8, 267.  | 1.0 | 4         |
| 792 | HIV-2 Infection in high-risk individuals in Spain. <i>Transfusion Science</i> , 1993, 14, 167-172.  | 0.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 793 | HTLV-I/II Infections in Spain. <i>International Journal of Epidemiology</i> , 1993, 22, 716-719.  | 0.9 | 35        |
| 794 | Kussmaul respiration and abdominal pain secondary to metabolic acidosis in AIDS patients with disseminated <i>Mycobacterium avium</i> complex infection receiving clofazimine. <i>Aids</i> , 1993, 7, 894.                        | 1.0 | 1         |
| 795 | Pyomyositis in patients with HIV infection. <i>Aids</i> , 1993, 7, 1020-1021.   | 1.0 | 10        |
| 796 | Prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Aids</i> , 1993, 7, 1133.  | 1.0 | 2         |
| 797 | Misdiagnosis of HTLV-II infection using HTLV-I screening assays. <i>Aids</i> , 1993, 7, 1395.   | 1.0 | 9         |
| 798 | Insufficiencies of the New WHO Western Blot Criteria in the Diagnosis of HIV-1 and HIV-2 Infections. <i>Vox Sanguinis</i> , 1992, 62, 191-192.  | 0.7 | 3         |
| 799 | Significance of Positive Polymerase Chain Reaction Results in HIV-Seronegative Individuals. <i>Vox Sanguinis</i> , 1992, 63, 287-288.   | 0.7 | 2         |
| 800 | Multifocal splenic abscesses caused by <i>Mycobacterium tuberculosis</i> in HIV-infected drug users. <i>Aids</i> , 1991, 5, 901.  | 1.0 | 8         |
| 801 | Non-Parenteral Transmission of Hepatitis C Virus. <i>International Journal of STD and AIDS</i> , 1991, 2, 449-450.  | 0.5 | 0         |
| 802 | Human Herpesvirus 6 in Spain: Seroprevalence in Blood Donors and Patients with Lymphoproliferative Disorders or HIV Infection. <i>Vox Sanguinis</i> , 1991, 60, 63-64.  | 0.7 | 0         |
| 803 | Synthetic Peptide Immunoassay for Diagnosis of HIV 2 Infection. <i>Vox Sanguinis</i> , 1989, 57, 222-222.   | 0.7 | 2         |
| 804 | HIV-2 in Spanish Drug Abusers. <i>Vox Sanguinis</i> , 1989, 57, 157-157.  | 0.7 | 0         |
| 805 | Serological Markers of Human Immunodeficiency Virus Infection in African Patients with AIDS: Are They Different from Markers Found in Patients from Other Countries?. <i>Journal of Infectious Diseases</i> , 1988, 158, 894-894. | 1.9 | 0         |